莎普爱思(603168.SH)：获得去氧肾上腺素酮咯酸溶液临床试验批准通知书

Core Viewpoint - The company, Shapais (603168.SH), has received approval from the National Medical Products Administration for a clinical trial of deoxycorticosterone ketone solution, indicating a significant step in its product development pipeline [1] Group 1: Clinical Trial Approval - The company has obtained the clinical trial approval notice (No. 2025LP03018) for deoxycorticosterone ketone solution [1] - The clinical trial is planned to be conducted once conditions are met [1] Group 2: Product Application - The product is primarily intended for use during cataract surgery or artificial lens replacement surgery to maintain pupil dilation, prevent pupil constriction during surgery, and alleviate postoperative eye pain [1]